ReviewJournal of thoracic disease2025
Systematic review of lung cancer with breast metastasis.
Review in Journal of thoracic disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Metastases to the Male Breast: A Systematic Review.Cancers · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Lung cancer with metastatic spread to the breast is a rare entity that is not commonly considered on the differential of diagnoses in the clinical context of new breast masses. The aim of our study is to provide a comprehensive literature review to highlight key clinical and histological features. Methods: A comprehensive review of literature from 1962 to 2024 regarding lung cancer with breast metastasis using PubMed was performed alongside an exemplary patient description. Data collection consisted of variables categorized as patient demographics, clinical disease characteristics, tumor immunohistochemistry and biomarker profile, and disease management and clinical outcomes. Results: Eighty-three studies consisting of case reports and case series were used for data collection and analysis, which consisted of 145 unique patient profiles. Of the included patients, 65.5% had adenocarcinoma, which was consistent with the reported chemical staining and molecular profiles; 49.6% had metachronous metastatic and primary disease with an average time to breast diagnosis of 24.2 months; 66.2% presented with an additional site of metastatic disease; 24.5% were initially misdiagnosed as having primary breast cancer. The overall mortality was 62.5% of those with reported survival outcomes, with an average follow-up of 15.0 months. Conclusions: Patients with lung cancer who have metastasized to the breast are at elevated risk for being misdiagnosed with primary breast cancer and may receive unnecessary surgery and incorrect treatment regimens.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.